Shingles Vaccine Approved in India
GlaxoSmithKline (GSK) Pharmaceuticals Ltd today announced the launch of its Shingrix® vaccine to prevent shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years and above in India.
PTI reported Shingrix can provide at least ten years of protection against shingles, which is caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox, GSK said in a statement on April 24, 2023.
In the U.S., the CDC's Morbidity and Mortality Weekly Report confirmed that on January 21, 2022, the Advisory Committee on Immunization Practices recommended two doses (0.5 mL each) to prevent herpes zoster and related complications in immunodeficient or immunosuppressed adults.
Singrix was initially approved in the U.S. in 2017 and Europe in 2018 and is now available in over 20 countries in 2023.
Our Trust Standards: Medical Advisory Committee
